The inverse trend observed in our serum data may suggest that IDO-1 activity is largely confined to the tumor microenvironment, limiting its systemic release, or that compensatory immune mechanisms reduce circulating IDO-1 levels in LC patients. This evidence concerns the gene IDO1 and neoplasm.